Chevy Chase Trust’s Vanda Pharmaceuticals VNDA Stock Holding History

Chevy Chase Trust’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100	Closed	-$2K	–	1027
2019 Q4	$2K	Buy	+100	New	+$1.51K	﹤0.01%	1143

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Chevy Chase Trust's VNDA Position: Q1 2020 in Review

Chevy Chase Trust sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 100 shares — an estimated $2K sold.

Chevy Chase Trust first reported a position in VNDA in Q4 2019 and held it in 1 quarter. The position peaked at $2K in Q4 2019. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

Chevy Chase Trust reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Chevy Chase Trust sold 100 Vanda Pharmaceuticals shares in Q1 2020, an estimated $2K.
Chevy Chase Trust first reported a position in Vanda Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Chevy Chase Trust's Vanda Pharmaceuticals position peaked at $2K in Q4 2019.
159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Chevy Chase Trust's 13F filing for Q1 2020, filed 13 May 2020.